Beyond 200 mg/mL: The Science and Scaling of High-Dose Biologics

Episode 39

0:00-30:53

Pushing biologics beyond 200 mg/mL isn’t just a formulation challenge - it’s a delivery, manufacturing, and regulatory challenge too. Aggregation, precipitation, and sky-high viscosity make scaling these therapies a gauntlet for drug developers. In this episode of Life Science Solutions, host Chris Adkins continues the conversation on hyper-concentrated biologics with Ryan Doxey, VP of Tech Ops & CMC at Kymanox, and Nick Letourneau, PhD, Associate Director of Product Development & Commercialization. Together, they unpack how dehydrated protein microparticles suspended in hydrophobic carriers (like MCT oils or ethyl oleate) can dissolve instantly upon injection, and why this breakthrough could dramatically ease the patient experience. The conversation dives deep into what this means for manufacturing, device compatibility, and regulatory pathways, revealing how the future of injectables depends on solving problems once thought unsolvable.

Publisher

Life Science Solutions

Link

share.transistor.fm/s/18ad3912

Published

October 20, 2025

Duration

31 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Kymanox

LS

Life Science Solutions

@lifesciencesolutions

#scaling #high #dosebiologics #lifesciences

The Nile